Antipsychotic polypharmacy in Schizophrenia: Benefits and risks

CNS Drugs

Volumn 25, Issue 5, 2011, Pages 383-399

  Barnes, Thomas R E ^a   Paton, Carol ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Prescribing; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SULPIRIDE; ZIPRASIDONE; ZUCLOPENTHIXOL;

DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; MONOTHERAPY; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 79953859675     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11587810-000000000-00000     Document Type: Review

References (154)

1. Gaebel W, Weinmann S, Sartorius N, et al. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry 2005; 187: 248-55 (Pubitemid 41306106)
2. Royal Australian and New Zealand College of Psychiatrists. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39: 1-30
3. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Clinical guideline 82, 2009 [online]. Available from URL http://guidance.nice.org.uk/CG82 [Accessed 2010 Aug 26]
4. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines. 10th ed. London: Informa Healthcare, 2009
5. Miller AL. PORT treatment recommendations. Schizophr Bull 2004; 30: 601-4 (Pubitemid 39625700)
6. Sheppard C, Collins L, Fiorentino D, et al. Polypharmacy in psychiatric treatment: incidence at a state hospital. Curr Ther Res 1969; 11: 765-74
7. Keks NA, Alston K, Hope J, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999; 33: 896-901 (Pubitemid 30015857)
8. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 Suppl.: S35-40
9. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalised psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700-6 (Pubitemid 38445515)
10. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003; 64: 984-9 (Pubitemid 37158242)
11. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among medical beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv 2007; 58: 1007-10 (Pubitemid 47122882)
12. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005; 5: 26
13. Marchand J, Grignon S. A case-control study of patients with resistant schizophrenia after clozapine discontinuation. J Clin Psychopharmacol 2007; 27: 90-2
14. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-51 (Pubitemid 27485972)
15. Milton J, Lawton J, Smith M, et al. Hidden high-dose antipsychotic prescribing: effects of p.r.n doses. Psych Bull 1998; 22: 675-7 (Pubitemid 28505802)
16. Tibaldi G, Munizza C, Bollini P, et al. Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Psychiatr Serv 1997; 48: 213-7 (Pubitemid 27057405)
17. Harrington M, Lelliott C, Paton C, et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull 2002; 26: 414-8 (Pubitemid 35331238)
18. Paton C, Barnes TRE, Cavanagh MR, et al. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry 2008; 192: 435-9 (Pubitemid 351809896)
19. Hung GBK, Cheung HK. Predictors of high-dose anti-psychotic prescription in psychiatric patients in Hong Kong. Hong Kong Med J 2008; 14: 35-9
20. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192-208 (Pubitemid 38380844)
21. Royal College of Psychiatrists. Revised consensus statement on high dose antipsychotic medication (council report CR138). London: Royal College of Psychiatrists, 2006
22. Taylor D, Atkinson J, Fischetti C, et al. A prospective 6-month analysis of the naturalistic use of aripiprazole: factors predicting favourable outcome. Acta Psychiatr Scand 2007; 116: 461-6 (Pubitemid 350086149)
23. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schi-zoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28: 392-400
24. Sparshatt A, Taylor D, Patel MX, et al. Amisulpride-dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009; 120: 416-28
25. Paton C, Lelliott P, Harrington M, et al. Patterns of anti-psychotic and anticholinergic prescribing for hospital in-patients. J Psychopharmacol 2003; 17: 223-9 (Pubitemid 36753540)
26. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89: 91-100 (Pubitemid 44881290)
27. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schiz Res 2009; 113: 1-11
28. Joukamaa M, Heliovaara M, Knekt P, et al. Schizo-phrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-7
29. Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010; 71: 103-8
30. Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006; 86: 138-46 (Pubitemid 44234045)
31. Chakos MH, Glick ID, Miller AL, et al. Baseline use of con-comitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006; 57: 1094-101 (Pubitemid 44204901)
32. Elie D, Poirier M, Chianetta JM, et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol 2010; 24: 1037-44
33. Pope A, Adams C, Paton C, et al. Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry 2010; 197: 67-72
34. Freudenreich O, Goff DC. Antipsychotic combination ther-apy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 23-30
35. Pandurangi AK, Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatric Pract 2008; 14: 345-67
36. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schiz Bull 2002; 28: 105-9 (Pubitemid 34534754)
37. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for anti-psychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164: 1404-10 (Pubitemid 47461141)
38. Hoffer ZS, Roth RL, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009; 50: 317-24
39. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13: 1115-25
40. Masopust J, Tuma I, Libiger J. Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Neuro Endocrinol Lett 2008; 29: 435-7
41. Henderson DC, Kunkel L, Nguyen DD, et al. An ex-ploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113: 142-7 (Pubitemid 43340908)
42. Kreyenbuhl J, Marcus SC, West JC, et al. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv 2007; 58: 983-90 (Pubitemid 47122878)
43. Bitter I, Treuer T, Dyachkova Y, et al. Antipsychotic pre-scription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Neuropsychopharmacol 2008; 18: 170-80
44. Stahl SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60: 425-6 (Pubitemid 29369795)
45. Kingsbury SJ, Yi D, Simpson GM. Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv 2001; 52: 1033-6
46. Langan J, Shajahan P. Antipsychotic polypharmacy: re-view of mechanisms, mortality and management. Psychiatrist 2010; 34: 58-62
47. Curson DA, Barnes TRE, Bamber RW, et al. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry 1985; 146: 469-74
48. Barnes TRE, Shingleton-Smith A, Paton C. Treatment of schizophrenia by long-acting depot injections in the UK. Br J Psychiatry 2009; 195 Suppl. 52: s37-42
49. Taylor D, Mir S, Mace S, et al. Coprescribing of atypical and typical antipsychotics-prescribing sequence and documented outcome. Psychiatr Bull 2002; 26: 170-2 (Pubitemid 34525132)
50. Nielsen J, Dahm M, Lublin H, et al. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24: 965-71
51. Prescribing Observatory for Mental Health. Topic 3 report 3b: prescribing of high-dose and combined antipsychotics for patients on forensic wards -re-audit. CRTU060, 2008. (Data on file)
52. TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus pro-methazine. BMJ 2003; 327: 708-13
53. Alexander J, Tharyan P, Adams C, et al. Rapid tranquilli-sation of violent or agitated patients in a psychiatric emergency setting: pragmatic randomized trial of intramuscular lorazepam v haloperidol plus promethazine. Br J Psychiatry 2004; 185: 63-9 (Pubitemid 38951631)
54. Whicher E, Morrison M, Douglas-Hall P. 'As required' med-ication regimens for seriously mentally ill people in hospital (review). Cochrane Database Syst Rev 2002; (3): CD003441
55. Usher K, Lindsay D, Sellen J. Mental health nurses' PRN psychotropic medication administration practices. J Psychiatr Mental Health Nurs 2001; 8: 383-90 (Pubitemid 33692178)
56. Usher L, Luck L. Psychotropic PRN: a model for best practice management of acute psychotic behavioural disturbance in inpatient psychiatric settings. Int J Mental Health Nurs 2004; 13: 18-21
57. Baker JA, Lovell K, Harris N. Mental health professionals' psychotropic pro re nata (p.r.n.) medication practices in acute inpatient mental health care: a qualitative study. Gen Hosp Psychiatry 2007; 29: 163-8
58. Ito A, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005; 187: 243-7 (Pubitemid 41306105)
59. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2006; 187: 243-7 (Pubitemid 41306105)
60. Geffen J, Cameron A, Sorensen L, et al. Pro re nata med-ication for psychoses: the knowledge and beliefs of doctors and nurses. Aust NZ J Psychiatry 2002; 36: 642-8 (Pubitemid 35174404)
61. Volavka J, Citrome L. Heterogeneity of violence in schi-zophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62: 1237-45 (Pubitemid 351977615)
62. Swanson JW, Swartz NS, Van Dorn RA, et al. Comparison of antipsychotic effects on reducing violence in people with schizophrenia. Br J Psychiatry 2008; 193: 37-43 (Pubitemid 351946806)
63. Citrome L, Volavka J, Czobar P, et al. Effect of clozapine, olanzapine, risperidone and haloperidol on hostility among people with schizophrenia. Psychiatr Serv 2001; 52: 1510-4
64. Krakowski MI, Czobor P, Citrome L, et al. Atypical anti-psychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psych 2006; 63: 622-9 (Pubitemid 43848293)
65. Mortimer AM, Singh P, Shepherd CJ, et al. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses 2010; 4: 49-55
66. Chan J, Sweeting MJ. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 2007; 21: 657-64 (Pubitemid 47472722)
67. Pae CU, Chiesa A, Mandelli L, et al. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. Clin Drug Investig 2010; 30: 187-93
68. Kane JM, Correll CU, Goff DC, et al. A multicenter, ran-domized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009; 70: 1348-57
69. Suzuki T, Uchida H, Watanabe K, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and ris-peridone. Hum Psychopharmacol 2008; 23: 455-63
70. Correll CU, Rummel-Kluge C, Corves C, et al. Anti-psychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35: 443-57
71. Kreyenbuhl JA, Valenstein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007; 58: 489-95 (Pubitemid 46640639)
72. Godleski LS, Kerler R, Barber JW, et al. Multiple versus single antipsychotic drug treatment in chronic psychosis. J Nerv Ment Dis 1989; 177: 686-9 (Pubitemid 19281804)
73. Yuzda MSK. Combination antipsychotics: what is the evidence? J Inform Pharmacother 2000; 2: 300-5
74. Goren JL, Parks JJ, Ghinassi FA, et al. When is anti-psychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008; 34: 571-82
75. Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf 2008; 31: 7-20
76. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schiz Bull 2010; 36: 71-93
77. Lerner V, Libov I, Kotler M, et al. Combination of 'atypical' antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 89-98 (Pubitemid 37548501)
78. Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-26 (Pubitemid 32289814)
79. Pani L, Villagran JM, Kontaxakis VP, et al. Practical issues with amisulpride in the management of patients with schizophrenia. Clin Drug Investig 2008; 28: 465-77 (Pubitemid 351948049)
80. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409-15 (Pubitemid 41318007)
81. Genç Y, Taner E, Candansayar S. Comparison of cloz-apine- amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007; 24: 1-13 (Pubitemid 46700860)
82. Josiassen RC, Ashok J, Kohegyi E, et al. Clozapine aug-mented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-6 (Pubitemid 40095682)
83. Yagcioglu AEA, Akdede BBK, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with ris-peridone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66: 63-72
84. Weiner E, Conley RR, Ball MP, et al. Adjunctive risper-idone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology 2010; 35 (10): 2274-83
85. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-82 (Pubitemid 43200298)
86. Freudenreich O, Henderson DC, Walsh JP, et al. Risper-idone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007; 92: 90-4 (Pubitemid 46561216)
87. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-73 (Pubitemid 27527329)
88. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008 Jan; 41 (1): 24-8 (Pubitemid 351195889)
89. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmen-tation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 720-31 (Pubitemid 351838681)
90. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with cloz-apine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13 (8): 1115-25
91. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizo-phrenia: an open clinical study. Clin Neuropharmacol 2005; 28: 220-4 (Pubitemid 41579619)
92. Henderson DC, Fan X, Copeland PM, et al. Ziprasidone as an adjuvant for clozapine-or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009; 24: 225-32
93. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009; (3): CD006324
94. Wang J, Omori IM, Fenton M, et al. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010; (1): CD008125
95. Paton C, Whittington C, Barnes TRE. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 2007; 27: 198-204 (Pubitemid 46594939)
96. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009; 119: 419-25
97. Barbui C, Signoretti A, Mule S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35: 458-68
98. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996; 153: 735-6 (Pubitemid 26133638)
99. Chong SA, Tan CH, Lee HS. Atrial ectopics with cloz-apine-risperidone combination. J Clin Psychopharmacol 1997; 17: 130-1
100. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, et al. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 407-9 (Pubitemid 34038074)
101. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002; 28: 5-16 (Pubitemid 34534746)
102. Kiivet RA, Llerena A, Dahl M-L, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995; 40: 467-76
103. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 161 (2 Suppl.): 1-56
104. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28: 75-84 (Pubitemid 34534751)
105. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002; 63: 93-4 (Pubitemid 34173843)
106. Stahl SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 2004; 7: 113-6 (Pubitemid 38823277)
107. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999; 12: 179-88 (Pubitemid 29446503)
108. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf 2003; 12: 41-8 (Pubitemid 36192948)
109. De Hert M, Wampers M, Peuskens J. Pharmacological treat-ment of hospitalised schizophrenic patients in Belgium. Int J Psychiatry Clin Pract 2006; 10: 285-90 (Pubitemid 44721771)
110. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001; 46: 334-9 (Pubitemid 32531565)
111. Hemminki E. Polypharmacy among psychiatric patients. Acta Psychiatr Scand 1977; 56: 347-56 (Pubitemid 8225422)
112. Bret P, Bonnet F, Bret MC, et al. Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux): analysis of prescribing practices for amisulpride, clozapine, olanzapine and risperidone. Encephale 2002; 28: 329-42
113. Bret P, Bret MC, Queuille E. Prescribing patterns of anti-psychotics in 13 French psychiatric hospitals. Encephale 2009; 35: 129-38
114. Hamann J, Ruppert A, Auby P, et al. Antipsychotic pre-scribing patterns in Germany: a retrospective analysis using a large outpatient prescription database. Int Clin Psychopharmacol 2003; 18: 237-42 (Pubitemid 36871875)
115. Yosselson-Superstine S, Sternik D, Liebenzon D. Pre-scribing patterns in psychiatric hospitals in Israel. Acta Psychiatr Scand 1979; 60: 477-82 (Pubitemid 10213358)
116. Biancosino B, Barbui C, Marmai L, et al. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol 2005; 20: 305-9 (Pubitemid 41475319)
117. Yoshimura R, Okamoto T, Nakamura J, et al. Prescription pattern of antipsychotic drugs for schizophrenic in-patients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics study. Psychiatry Clin Neurosci 2006; 60: 778-9 (Pubitemid 44736610)
118. Yip K, Ungvari G, Lau S. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J (Engl) 1997; 110: 792-6 (Pubitemid 27443738)
119. Chong S-A, Sachdev P, Mahendran R, et al. Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore. Aust NZ J Psychiatry 2000; 34: 988-91
120. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58: 178-83 (Pubitemid 39043998)
121. Broekema WJ, de Groot IW, van Harten PN. Simulta-neous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics: a European study. Pharm World Sci 2007; 29: 126-30 (Pubitemid 46872979)
122. Remington G, Shammi CM, Sethna R, et al. Antipsychotic dosing patterns for schizophrenia in three treatment settings. Psychiatr Serv 2001; 52: 96-8 (Pubitemid 32039813)
123. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28: 17-29 (Pubitemid 34534747)
124. Tapp A, Wood AE, Secrest L, et al. Combination anti-psychotic therapy in clinical practice. Psychiatr Serv 2003; 54: 55-9 (Pubitemid 36043847)
125. Essock SM, Covell NH, Leckman-Westin E, et al. Identi-fying clinically questionable psychotropic prescribing practices for medicaid recipients in New York State. Psychiatr Serv 2009; 60: 1595-602
126. Tungaraza TE, Gupta S, Jones J, et al. Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist 2010; 34: 44-6
127. Hermann RC, Yang D, Ettner SL, et al. Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. Psychiatr Serv 2002; 53: 425-30
128. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004; 65: 1377-88
129. Prescribing Observatory for Mental Health. Using the Prescribing Observatory for Mental Health to generate data on prescribing practices relating to people with schizophrenia and bipolar disorder. MHRN commissioned report, 2009. (Data on file)
130. Prescribing Observatory for Mental Health. Topic 1e sup-plementary report: prescribing of high-dose and combination antipsychotics on adult acute and intensive care wards. CRTU088, 2010. (Data on file)
131. Prescribing Observatory for Mental Health. Topic 2 report 2b: screening for metabolic side effects of antipsychotic drugs in patients treated by assertive outreach teams. 12-month re-audit, 2007. (Data on file)
132. McCombs JS, Nichol MB, Johnstone BM, et al. Anti-psychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Serv 2000; 51: 525-7 (Pubitemid 30212098)
133. Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm 2003; 64 Suppl.: 105-17 (Pubitemid 38339965)
134. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration: New York metropolitan region. Schizophr Bull 2002; 28: 31-42 (Pubitemid 34534748)
135. Sohler NL, Walkup J, McAlpine D, et al. Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. Psychiatr Serv 2003; 54: 1258-63 (Pubitemid 37055988)
136. Benson PR. Factors associated with antipsychotic drug prescribing by southern psychiatrists. Med Care 1983; 21: 639-54
137. Diaz FJ, De Leon J. Excessive antipsychotic dosing in 2 U.S. State hospitals. J Clin Psychiatry 2002; 63: 998-1003 (Pubitemid 35388058)
138. Herlihy D, Chatterjee A, Gwenzi S, et al. Low violence rates on PICU despite reduction in use of combination or high-dose antipsychotic prescribing [abstract]. J Psychopharmacol 2010; 24 (3 Suppl.): A14
139. Sernyak MJ, Dausey D, Desai R, et al. Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv 2003; 54: 246-8 (Pubitemid 36752858)
140. Falzer PR, Garman DM, Moore BA. Examining the in-fluence of clinician decision making on adherence to a clinical guideline. Psychiatr Serv 2009; 60: 698-701
141. Chilvers R, Harrison G, Sipos A, et al. Evidence into practice: application of psychological models of change in evidence-based implementation. Br J Psychiatry 2002; 181: 99-101 (Pubitemid 34864489)
142. Drake RE, Bond GR, Essock SM. Implementing evidence-based practices for people with schizophrenia. Schizophr Bull 2009; 35: 704-13
143. Bero LA, Grilli R, Grimshaw JM, et al. Getting research findings into practice: closing the gap between research and practice -an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998; 317: 465-8 (Pubitemid 28368041)
144. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68: 1751-62 (Pubitemid 350247505)
145. Toprac MG, Dennehy EB, Carmody TJ, et al. Im-plementation of the Texas Medication Algorithm Project Patient and Family Education Program. J Clin Psychiatry 2006; 67: 1362-72 (Pubitemid 44583383)
146. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500-8
147. Constantine RJ, Andel R, Tandon R. Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment Health J 2010; 46 (6): 523-30
148. Patrick V, Schleifer SJ, Nurenberg JR, et al. An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006; 57: 21-3 (Pubitemid 43053830)
149. Chong S-A, Ravichandran N, Poon L-Y, et al. Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore 2006; 35: 457-60 (Pubitemid 44450149)
150. Thompson A, Sullivan SA, Barley M, et al. The DEBIT trial: an intervention to reduce antipsychotic polypharmacy pre-scribing in adult psychiatry wards -a cluster randomized controlled trial. Psychol Med 2008; 38: 705-15 (Pubitemid 351483230)
151. Thompson A, Sullivan S, Barley M, et al. Effectiveness of a cognitive behavioural workbook for changing beliefs about antipsychotic polypharmacy: analysis from a cluster randomized controlled trial. J Eval Clin Pract 2010; 16: 520-8
152. Bowden MF. Audit: prescription of 'as required' (p.r.n.) medication in an in-patient setting. Psychiatr Bull 1999; 23: 413-6 (Pubitemid 29317438)
153. Thapa PB, Palmer SL, Owen RR, et al. PRN (as needed) orders and exposure of psychiatric inpatients to unnecessary psychotropic medications. Psychiatr Serv 2003; 54: 1282-6 (Pubitemid 37055992)
154. Donat DC. Impact of a clinical-administrative review procedure on reducing reliance on psychotropic PRN medication. Psychiatr Rehab J 2006; 29: 215-8 (Pubitemid 43153121)